Blueprint MedicinesBPMC
13F holders, Q4 2025 (December 31)2holders −3
0new positions
3sold out
$99.45avg. 13F price*
At the end of Q4 2025, 2 institutions reported holding Blueprint Medicines Corp. (BPMC) in their 13F filings, down 3 from Q3 2025. 0 opened new positions and 3 sold out. The largest holders were DekaBank Deutsche Girozentrale ($2.6M) and Huntington National Bank ($129).
- Company
- Blueprint Medicines Corp.
- CUSIP
- 09627Y109
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 3 | $28K |
All 13F filers, Q3 2025 → Q4 2025: 221 shares sold, net −221 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| DekaBank Deutsche Girozentrale | 0.00% | No change | 25,883 | $2.6M |
| Huntington National Bank | 0.00% | No change | 1 | $129 |
"% of holder's portfolio" is BPMC's weight in each manager's 13F, not the share of Blueprint Medicines Corp. the manager owns.